tiprankstipranks
Trending News
More News >
Sectra AB Class B (SE:SECT.B)
:SECT.B

Sectra AB Class B (SECT.B) AI Stock Analysis

Compare
3 Followers

Top Page

SE:SECT.B

Sectra AB Class B

(SECT.B)

Select Model
Select Model
Select Model
Neutral 67 (OpenAI - 5.2)
Rating:67Neutral
Price Target:
kr230.00
▼(-8.15% Downside)
Action:ReiteratedDate:03/07/26
The score is primarily supported by strong financial performance (rapid TTM growth, strong margins, and very low leverage with robust ROE). It is held back by a mixed-to-weak technical trend (negative MACD and below longer-term moving averages) and especially by expensive valuation (very high P/E and low yield).
Positive Factors
Rapid Revenue Acceleration
A sustained large uplift in TTM revenue indicates strong demand and successful go-to-market execution across software licensing and services. Over 2–6 months this suggests expanding market penetration and higher recurring contract base that can compound future revenue.
High and Durable Profitability
Consistently strong operating and net margins point to pricing power, efficient cost structure, and scalable software-centric economics. These margins enable reinvestment in R&D and sales, supporting product leadership and durable cash generation over the medium term.
Conservative Balance Sheet and Strong ROE
Very low leverage paired with high ROE gives financial flexibility to fund growth, pursue partnerships or acquisitions, and withstand downturns. The capital-light software model combined with strong equity returns supports sustainable strategic options.
Negative Factors
Declining Free Cash Flow
A notable TTM FCF decline signals working-capital or collection variability that can reduce internal funding for capex, R&D, or acquisitions. Over months this raises the chance of tighter near-term liquidity and greater reliance on operational execution to restore cash conversion.
Margin and Gross-Profit Variability
Significant year-to-year margin swings imply sensitivity to product mix, pricing pressure, or cost volatility. This undermines longer-term margin predictability, complicates forecasting and budgeting, and increases execution risk for sustaining high profitability.
High Expectations Leave Little Room for Error
Elevated profitability raises external expectations; any slowdown or execution miss could disproportionately impact perceived stability and capital access. Structurally, this increases downside risk over the medium term if growth or margin performance softens.

Sectra AB Class B (SECT.B) vs. iShares MSCI Sweden ETF (EWD)

Sectra AB Class B Business Overview & Revenue Model

Company DescriptionSectra AB Class B (SECT.B) is a Swedish company specializing in medical technology and cybersecurity solutions. It operates primarily in the healthcare sector, offering products and services that enhance medical imaging, radiology, and pathology. Sectra's core offerings include advanced imaging software for radiology and breast imaging, as well as solutions for managing and sharing medical images securely. Additionally, the company provides cybersecurity solutions for protecting sensitive information within the healthcare sector.
How the Company Makes MoneySectra generates revenue through a combination of software licensing, maintenance contracts, and professional services related to its medical imaging and cybersecurity solutions. Key revenue streams include recurring revenues from long-term contracts with healthcare providers for software maintenance and support, as well as one-time sales from new software licenses and equipment. The company also benefits from partnerships with healthcare organizations and technology providers, which can enhance its market reach and provide tailored solutions to clients. Additionally, Sectra's focus on innovation in imaging technology and cybersecurity helps to secure ongoing demand for its products and services.

Sectra AB Class B Financial Statement Overview

Summary
Strong financial profile with sharply accelerating TTM revenue (+~129%), solid profitability (operating margin ~24%, net margin ~19%), and a conservatively levered balance sheet (debt-to-equity ~0.05) supporting strong ROE (low-30% range). Score is tempered by notable margin variability across years and uneven cash-flow conversion, including a TTM free-cash-flow decline (~-18%) despite good FCF-to-net-income (~0.92x).
Income Statement
88
Very Positive
TTM (Trailing-Twelve-Months) revenue accelerated sharply (about +129% vs the prior annual period), with strong profitability: operating margin around 24% and net margin around 19%. Earnings are solid and consistent over time, but margins and gross profit levels show notable swings across years (including unusually low gross margin in 2025 and unusually high levels in 2021–2022), which adds some quality/consistency risk to the trend.
Balance Sheet
92
Very Positive
Balance sheet is conservatively positioned with very low leverage (debt-to-equity ~0.05 in TTM (Trailing-Twelve-Months)), and equity has steadily expanded over the period. Returns on equity are strong (low-30% range in TTM (Trailing-Twelve-Months)), signaling efficient capital use; the main drawback is that profitability is high enough that investors may expect continued execution, leaving less room for operational disappointment.
Cash Flow
80
Positive
Cash generation is strong in absolute terms in TTM (Trailing-Twelve-Months), with free cash flow close to net income (roughly 0.92x), supporting earnings quality. However, free cash flow declined year over year (about -18% in TTM (Trailing-Twelve-Months)) and cash conversion has been uneven historically (notably weak in 2024), indicating potential working-capital volatility and less predictable near-term cash flow trajectory.
BreakdownTTMApr 2024Apr 2023Apr 2022Apr 2021Apr 2020
Income Statement
Total Revenue3.42B3.24B2.96B2.35B1.95B1.63B
Gross Profit1.87B543.41M557.55M488.91M1.71B1.48B
EBITDA784.05M795.35M615.06M538.55M477.28M429.01M
Net Income537.49M563.37M428.39M374.96M314.79M275.51M
Balance Sheet
Total Assets4.05B3.76B3.21B2.74B2.19B1.65B
Cash, Cash Equivalents and Short-Term Investments1.35B1.34B804.64M945.24M808.77M454.85M
Total Debt109.51M87.46M31.79M82.26M62.62M73.45M
Total Liabilities2.12B1.84B1.64B1.44B1.11B756.33M
Stockholders Equity1.93B1.92B1.57B1.30B1.08B895.62M
Cash Flow
Free Cash Flow727.41M812.37M75.58M347.70M542.55M304.53M
Operating Cash Flow799.99M922.36M326.33M440.49M616.92M372.19M
Investing Cash Flow-136.29M-113.86M-130.74M-212.79M-68.35M-66.82M
Financing Cash Flow-448.49M-251.88M-222.20M-219.29M-198.75M-198.69M

Sectra AB Class B Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price250.40
Price Trends
50DMA
210.64
Positive
100DMA
246.86
Negative
200DMA
290.10
Negative
Market Momentum
MACD
4.86
Negative
RSI
69.22
Neutral
STOCH
94.79
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SECT.B, the sentiment is Neutral. The current price of 250.4 is above the 20-day moving average (MA) of 196.07, above the 50-day MA of 210.64, and below the 200-day MA of 290.10, indicating a neutral trend. The MACD of 4.86 indicates Negative momentum. The RSI at 69.22 is Neutral, neither overbought nor oversold. The STOCH value of 94.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SECT.B.

Sectra AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
kr3.58B24.4917.89%1.61%1.53%0.79%
67
Neutral
kr45.42B68.3827.98%0.43%10.08%68.12%
57
Neutral
kr51.27B26.396.91%2.16%6.74%21.40%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
kr1.16B-1.36-50.36%-23.24%45.32%
49
Neutral
kr12.76B-3.703.34%0.80%-1.29%
49
Neutral
kr5.85B233.591.20%8.39%-85.36%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SECT.B
Sectra AB Class B
232.80
-15.05
-6.07%
SE:GETI.B
Getinge
188.25
-29.35
-13.49%
SE:VITR
Vitrolife AB
94.20
-81.21
-46.30%
SE:BICO
BICO Group AB Class B
16.49
-24.19
-59.46%
SE:CEVI
CellaVision AB
150.20
-18.85
-11.15%
SE:XVIVO
Xvivo Perfusion AB
185.80
-226.20
-54.90%

Sectra AB Class B Corporate Events

Sectra boosts cloud-driven recurring revenue as orders surge in nine-month 2025/2026 report
Mar 6, 2026

Sectra reported strong demand in its nine-month 2025/2026 interim period, highlighted by a 4.2% increase in contracted order bookings to SEK 6.05 billion and an 18.5% rise in recurring revenue, driven by a 57.5% surge in cloud recurring revenue. Net sales grew 7.9% to SEK 2.51 billion, and operating profit rose 21.1% to SEK 501.5 million excluding last year’s patent settlement, underscoring improved underlying profitability.

In the third quarter, contracted order bookings climbed 35% and cloud recurring revenue jumped 53.3%, though net sales growth was more modest at 5.1% and the operating margin eased to 21.8%. Cash flow from operations declined compared with the prior year’s elevated levels, but the company continues to benefit from high customer satisfaction and low churn, reinforcing its competitive position in enterprise imaging and supporting a shift toward higher-margin recurring cloud revenue.

The most recent analyst rating on ($SE:SECT.B) stock is a Hold with a SEK206.00 price target. To see the full list of analyst forecasts on Sectra AB Class B stock, see the SE:SECT.B Stock Forecast page.

Sectra Reports Strong Growth and Profitability in H1 2025/2026
Dec 12, 2025

Sectra reported significant growth in order bookings, sales, and profitability for the first half of 2025/2026, driven by high customer satisfaction and market expansion in North America. The company’s strong financial performance, highlighted by increased recurring and cloud revenues, underscores its strengthened market position and operational efficiency.

The most recent analyst rating on ($SE:SECT.B) stock is a Hold with a SEK321.00 price target. To see the full list of analyst forecasts on Sectra AB Class B stock, see the SE:SECT.B Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 07, 2026